Luigi Aurisicchio

ORCID: 0000-0003-3110-4534
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • Virus-based gene therapy research
  • Cancer Research and Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • SARS-CoV-2 and COVID-19 Research
  • CAR-T cell therapy research
  • RNA Interference and Gene Delivery
  • Cancer Immunotherapy and Biomarkers
  • vaccines and immunoinformatics approaches
  • Microbial Inactivation Methods
  • Animal Virus Infections Studies
  • Nanoplatforms for cancer theranostics
  • Cancer Cells and Metastasis
  • HER2/EGFR in Cancer Research
  • Veterinary Oncology Research
  • COVID-19 Clinical Research Studies
  • T-cell and B-cell Immunology
  • Viral gastroenteritis research and epidemiology
  • Lung Cancer Treatments and Mutations
  • Melanoma and MAPK Pathways
  • Bacillus and Francisella bacterial research
  • CRISPR and Genetic Engineering
  • interferon and immune responses
  • Peptidase Inhibition and Analysis
  • Lung Cancer Research Studies

AlmavivA (Italy)
2017-2023

Moffitt Cancer Center
2022

Etna Biotech (Italy)
2014-2022

Deutsches Archäologisches Institut, Abteilung Rom
2021-2022

Universitatea Națională de Știință și Tehnologie Politehnica București
2022

Biogem
2010-2021

Université Paris-Saclay
2021

Istituto di Farmacologia Traslazionale
2019

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2016

Institute of Molecular Biology and Pathology
2005-2013

Abstract There is a need for technologies to predict the efficacy of cancer treatment in individual patients. Here, we show that optical metabolic imaging organoids derived from primary tumors can therapeutic response xenografts and measure antitumor drug responses human tumor–derived organoids. Optical quantifies fluorescence intensity lifetime NADH FAD, coenzymes metabolism. As early as 24 hours after with clinically relevant anticancer drugs, index responsive decreased (P < 0.001)...

10.1158/0008-5472.can-14-0663 article EN Cancer Research 2014-08-07

Abstract COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation urgently impelled many companies and public research institutes to concentrate their efforts on for effective therapeutics. Here, we outline strategies targets currently adopted in developing vaccine against SARS-CoV-2. Based previous evidence experience with SARS MERS, primary focus been Spike protein, considered as ideal target immunotherapies.

10.1186/s12967-020-02392-y article EN cc-by Journal of Translational Medicine 2020-06-03

Spontaneous tumors in dog have been demonstrated to share many features with their human counterparts, including relevant molecular targets, histological appearance, genetics, biological behavior and response conventional treatments. Mammary therefore provide an attractive alternative more classical mouse models, such as transgenics or xenografts, where the tumour is artificially induced. To assess extent which represent clinically significant phenotypes, we performed first genome-wide...

10.1186/1471-2164-10-135 article EN cc-by BMC Genomics 2009-03-27

In recent years, studies of cancer development and recurrence have been influenced by the stem cells (CSCs)/cancer-initiating (CICs) hypothesis. According to this, is sustained highly positioned, chemoresistant with extensive capacity self renewal, which are responsible for disease relapse after chemotherapy. Growth as three-dimensional non-adherent spheroids regarded a useful methodology enrich endowed CSC-like features. We recently reported that cell cultures derived from malignant pleural...

10.1038/cddis.2013.444 article EN cc-by Cell Death and Disease 2013-12-05

Abstract Resistance to therapy and lack of curative treatments for metastatic breast cancer suggest that current therapies may be missing the subpopulation chemoresistant radioresistant stem cells (CSC). The ultimate success any treatment well rest on CSC eradication, but specific anti-CSC are still limited. A comparison transcriptional profiles murine Her2+ tumor TUBO their derived CSC-enriched tumorspheres has identified xCT, functional subunit cystine/glutamate antiporter system xc−, as a...

10.1158/0008-5472.can-15-1208 article EN Cancer Research 2015-11-14

// Sara Donzelli 1 , Federica Mori 2 Teresa Bellissimo Andrea Sacconi Beatrice Casini 3 Tania Frixa Giuseppe Roscilli 4 Luigi Aurisicchio Francesco Facciolo 5 Alfredo Pompili 6 Maria Antonia Carosi Edoardo Pescarmona Oreste Segatto 7 Greg Pond 8 Paola Muti Stefano Telera Sabrina Strano 2,8 Yosef Yarden 9 and Giovanni Blandino 1,8 Translational Oncogenomics Unit, Italian National Cancer Institute 'Regina Elena', Rome, Italy Molecular Chemoprevention Department of Pathology, Takis s.r.l.,...

10.18632/oncotarget.5930 article EN Oncotarget 2015-09-30

Abstract Background DNA electroporation has been demonstrated in preclinical models to be a promising strategy improve cancer immunity, especially when combined with other genetic vaccines heterologous prime-boost protocols. We report the results of 2 multicenter phase 1 trials involving adult patients (n=33) stage II-IV disease. Methods Patients were vaccinated V930 alone, vaccine containing equal amounts plasmids expressing extracellular and trans-membrane domains human HER2, plasmid CEA...

10.1186/1479-5876-11-62 article EN cc-by Journal of Translational Medicine 2013-03-08

Immune checkpoint inhibitors (ICI) based on anti-CTLA-4 (αCTLA-4) and anti-PD1 (αPD1) are being tested in combination with different therapeutic approaches including other immunotherapies such as neoantigen cancer vaccines (NCV). Here we explored, two murine models, combinations of ICI personalized DNA expressing neoantigens delivered by electroporation (EP). Anti-cancer efficacy was evaluated using or without CD4 epitopes. Therapeutic showed synergistic effects protocols established large...

10.1038/s41541-022-00433-9 article EN cc-by npj Vaccines 2022-02-02

ABSTRACT To characterize the induction of antigen-specific immune response mediated by baculovirus, vectors expressing E2 glycoprotein hepatitis C virus or carcinoembryonic antigen (CEA) under control cytomegalovirus immediate-early promoter-enhancer were constructed. Additionally, a baculovirus vector encoding (Bac-G-E2) and vesicular stomatitis (VSV-G) in viral envelope was generated inserting VSV-G coding sequence downstream polyhedrin promoter. Mice subjected to intramuscular,...

10.1128/jvi.78.16.8663-8672.2004 article EN cc-by Journal of Virology 2004-07-27

Abstract Purpose: Matrix metalloproteinases (MMP) are zinc-dependent endopeptidases that mediate numerous physiologic and pathologic processes, including matrix degradation, tissue remodeling, inflammation, tumor metastasis. To develop a vaccine targeting stromal antigens expressed by cancer-associated fibroblasts, we focused on MMP11 (or stromelysin 3). expression correlates with aggressive profile invasiveness of different types carcinoma. Experimental Design: show the efficacy MMP11,...

10.1158/1078-0432.ccr-08-3226 article EN Clinical Cancer Research 2009-06-15

Canine cancers occur with an incidence similar to that of humans and share many features human malignancies including histological appearance, tumor genetics, biological behavior, response conventional therapies. As observed in humans, the telomerase reverse transcriptase (TERT) activity is largely confined tissues absent majority normal dog tissues. Therefore, TERT (dTERT) can constitute a valid target for translational cancer immunotherapy. We have evaluated ability adenovirus serotype 6...

10.1038/mt.2010.104 article EN cc-by-nc-nd Molecular Therapy 2010-06-08

Malignant pleural effusions (MPEs) could represent an excellent source to culture a wide variety of cancer cells from different donors. In this study, we set up conditions for deriving MPEs several patients affected by the most frequent form lung cancer, namely subset non small cell cancers (NSCLC) classified as Lung Adenocarcinomas (AdenoCa) which account approximately 40% cases. AdenoCa malignant gave rise in vitro cultures both adherent and/or spheroid almost all cases analyzed. We...

10.1371/journal.pone.0021320 article EN cc-by PLoS ONE 2011-07-18

Abstract Background Treatment of advanced melanoma has been improved with the advent BRAF inhibitors. However, a limitation to such treatment is occurrence resistance. Several mechanisms have identified be responsible for development resistance, either MEK-dependent or MEK-independent. In order overcome resistance due reactivation MEK signaling, inhibitors are being clinically developed promising results. also in this case inevitably occurs. It recently reported that ErbB3, member EGFR...

10.1186/1479-5876-11-180 article EN cc-by Journal of Translational Medicine 2013-07-27

Lung cancer is the leading cause of related deaths and Malignant Pleural Effusion (MPE) a frequent complication. Current therapies suffer from lack efficacy in great percentage cases, especially when diagnosed at late stage. Moreover patients' responses vary outcome unpredictable. Therefore, identification patients who will benefit most chemotherapy treatment important for accurate prognostication better outcome. In this study, using malignant pleural effusions non-small cell lung (NSCLC)...

10.1186/s12967-016-0816-x article EN cc-by Journal of Translational Medicine 2016-02-29

Client-owned pet dogs represent exceptional translational models for advancement of cancer research because they reflect the complex heterogeneity observed in human cancer. We have recently shown that a genetic vaccine targeting dog telomerase reverse transcriptase (dTERT) and based on adenovirus DNA electro-gene-transfer (Ad/DNA-EGT) technology can induce strong cell-mediated immune responses against this tumor antigen increase overall survival affected by B-cell lymphosarcoma (LSA)...

10.1089/hum.2013.112 article EN Human Gene Therapy 2013-07-31

Personalized cancer vaccines based on neoantigens have reached the clinical trial stage in melanoma. Different vaccination protocols showed efficacy preclinical models without a clear indication of quality and number required for an effective vaccine. In effort to develop potent efficacious neoantigen-based vaccines, we developed different neoantigen minigene (NAM) vaccine vectors determine rules successful (NCV) delivered by plasmid DNA electroporation. Immune responses were analyzed at...

10.1186/s13046-019-1084-4 article EN cc-by Journal of Experimental & Clinical Cancer Research 2019-02-14

Abstract The immunogenic properties of plasmid DNA and recombinant adenovirus (Ad) encoding the carcinoembryonic antigen (CEA) were examined in mice by measuring both amplitude type immune response, immunogenicity codon usage optimized cDNA CEA (CEAopt) was assessed C57Bl/6 transgenic mice. Vectors injected into quadriceps muscle either alone or combination, electroporated to enhance gene expression efficiency immunogenicity. Injection pVIJ/CEA followed Ad‐CEA boost elicited highest CD4 +...

10.1002/ijc.21188 article EN International Journal of Cancer 2005-05-19
Coming Soon ...